{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T02:38:21Z","timestamp":1792636701573,"version":"4.5.0"},"reference-count":23,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T00:00:00Z","timestamp":1792368000000},"content-version":"vor","delay-in-days":18,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Johnson & Johnson, Canada"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,10,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Inflammatory bowel diseases (IBDs), including Crohn\u2019s disease (CD) and ulcerative colitis (UC), are increasingly prevalent. Ustekinumab (UST), a biologic therapy, has shown efficacy in treating CD and UC, but its real-world impact is less clear. This study assessed all-cause and IBD-specific healthcare resource utilization (HCRU) and costs, excluding medication costs, among patients with CD and UC initiated on UST.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective cohort study in Ontario, Canada included patients initiating UST between January 2017 and September 2022. Patients were identified through the Johnson &amp; Johnson (J&amp;J) BIOADVANCE\u00ae patient support program and deterministically linked to ICES databases. Outcomes were compared between 1 year pre-initiation of therapy and each post-initiation year (up to 4 years). Results were reported for patients who were persistent on UST at each year of the analysis period, patients who were persistent vs. discontinued UST for the duration of Year 1, and patients who were biologic-na\u00efve versus bio-experienced prior to index.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The study cohort included 2279 patients with CD and 626 patients with UC. UST initiation was associated with significant reductions (P\u2009&amp;lt;\u2009.001) in the number of all-cause HCRU events in each year of follow-up, including for CD patients who were biologic-na\u00efve and persistent on UST. Non-medication costs were lower for both CD and UC patients in all years, and significant in Years 1-3 for CD and Year 2 for UC patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In CD and UC patients, all-cause and IBD-specific HCRU and non-medication healthcare costs were lower in years following UST initiation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/crocol\/otag103","type":"journal-article","created":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T23:57:04Z","timestamp":1792627024000},"source":"Crossref","is-referenced-by-count":0,"title":["A real-world study of healthcare resource utilization and costs in patients with Crohn\u2019s disease and ulcerative colitis initiating ustekinumab treatment via Johnson &amp; Johnson\u2019s BIOADVANCE program"],"prefix":"10.1093","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4366-9076","authenticated-orcid":false,"given":"Laura","family":"Targownik","sequence":"first","affiliation":[{"name":"Department of Medicine, Division of Gastroenterology, University of Toronto , Toronto, ON,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eneda","family":"Pone","sequence":"additional","affiliation":[{"name":"Health Economics and Government Relations, Johnson & Johnson Canada Inc. , Toronto, ON,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7330-975X","authenticated-orcid":false,"given":"Martin G","family":"Latour","sequence":"additional","affiliation":[{"name":"Medical Affairs, Johnson & Johnson Canada Inc. , Toronto, ON,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kasra","family":"Boyerahmadi","sequence":"additional","affiliation":[{"name":"Medical Affairs, Johnson & Johnson Canada Inc. , Toronto, ON,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huijuan","family":"Yang","sequence":"additional","affiliation":[{"name":"Real World Solutions, IQVIA Solutions Canada, Inc. , Kirkland, QC,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juejing","family":"Ling","sequence":"additional","affiliation":[{"name":"Real World Solutions, IQVIA Solutions Canada, Inc. , Kirkland, QC,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4899-7885","authenticated-orcid":false,"given":"Ali","family":"Tehrani","sequence":"additional","affiliation":[{"name":"Real World Solutions, IQVIA Solutions Canada, Inc. , Kirkland, QC,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shane","family":"Golden","sequence":"additional","affiliation":[{"name":"Real World Solutions, IQVIA Solutions Canada, Inc. , Kirkland, QC,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0523-9032","authenticated-orcid":false,"given":"John K","family":"Marshall","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Gastroenterology, McMaster University , Hamilton, ON,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,10,19]]},"reference":[{"key":"2026102121470560500_otag103-B1","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.14309\/ajg.0000000000002687","article-title":"Forecasting the incidence and prevalence of inflammatory bowel disease: a Canadian nationwide analysis","volume":"119","author":"Coward","year":"2024","journal-title":"Am J Gastroenterol"},{"key":"2026102121470560500_otag103-B2","author":"Crohn\u2019s and Colitis Canada","year":"2023"},{"key":"2026102121470560500_otag103-B3","author":"The Economist Impact","year":"2023"},{"key":"2026102121470560500_otag103-B4","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1056\/NEJMoa1602773","article-title":"Ustekinumab as induction and maintenance therapy for Crohn\u2019s disease","volume":"375","author":"Feagan","year":"2016","journal-title":"N Engl J Med"},{"key":"2026102121470560500_otag103-B5","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1056\/NEJMoa1900750","article-title":"Ustekinumab as induction and maintenance therapy for ulcerative colitis","volume":"381","author":"Sands","year":"2019","journal-title":"N Engl J Med"},{"key":"2026102121470560500_otag103-B6","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1093\/ibd\/izac149","article-title":"Clinical, endoscopic, and radiological effectiveness of ustekinumab in bio-na\u00efve versus bio-experienced patients with Crohn\u2019s disease: real-world experience from a large Canadian center","volume":"29","author":"Sedano","year":"2023","journal-title":"Inflamm Bowel Dis"},{"key":"2026102121470560500_otag103-B7","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.dld.2023.08.042","article-title":"Real-world effectiveness and safety of ustekinumab in bio-naive patients with moderate-to-severe Crohn\u2019s disease: a Canadian multi-center study","volume":"56","author":"Bessissow","year":"2024","journal-title":"Dig Liver Dis"},{"key":"2026102121470560500_otag103-B8","doi-asserted-by":"publisher","first-page":"4421","DOI":"10.1007\/s12325-023-02611-0","article-title":"Real-world persistence of ustekinumab in the treatment of inflammatory bowel disease","volume":"40","author":"Bressler","year":"2023","journal-title":"Adv Ther"},{"key":"2026102121470560500_otag103-B9","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1093\/ibd\/izz063","article-title":"The effect of initiation of anti-TNF therapy on the subsequent direct health care costs of inflammatory bowel disease","volume":"25","author":"Targownik","year":"2019","journal-title":"Inflamm Bowel Dis"},{"key":"2026102121470560500_otag103-B10","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1155\/2011\/157604","article-title":"Health care resource use and costs for Crohn\u2019s disease before and after infliximab therapy","volume":"25","author":"Loomes","year":"2011","journal-title":"Can J Gastroenterol"},{"key":"2026102121470560500_otag103-B11","doi-asserted-by":"publisher","first-page":"96","DOI":"10.36469\/9791","article-title":"Analysis of healthcare resource utilization and costs after the initiation of biologic treatment in patients with ulcerative colitis and Crohn\u2019s disease","volume":"6","author":"Perera","year":"2018","journal-title":"J Health Econ Outcomes Res"},{"key":"2026102121470560500_otag103-B12","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1136\/gutjnl-2019-318440","article-title":"Introduction of anti-TNF therapy has not yielded expected declines in hospitalisation and intestinal resection rates in inflammatory bowel diseases: a population-based interrupted time series study","volume":"69","author":"Murthy","year":"2020","journal-title":"Gut"},{"key":"2026102121470560500_otag103-B13","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.1007\/s12325-020-01276-3","article-title":"Persistence, dose titration, and health care resource utilization among Crohn\u2019s disease patients treated with ustekinumab: a real-world analysis in the United States","volume":"37","author":"Obando","year":"2020","journal-title":"Adv Ther"},{"key":"2026102121470560500_otag103-B14","doi-asserted-by":"publisher","first-page":"otab011","DOI":"10.1093\/crocol\/otab011","article-title":"Persistence with biologic therapy and associated costs of patients with inflammatory bowel disease: a German retrospective claims data analysis","volume":"3","author":"Mahlich","year":"2021","journal-title":"Crohns Colitis 360"},{"key":"2026102121470560500_otag103-B15","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.1016\/j.dld.2024.04.017","article-title":"Healthcare resource utilization following ustekinumab initiation among bio-na\u00efve Canadian patients with moderately-to-severely active Crohn\u2019s disease","volume":"56","author":"Bessissow","year":"2024","journal-title":"Dig Liver Dis"},{"key":"2026102121470560500_otag103-B16","author":"ICES | About ICES data. ICES","year":"2024"},{"key":"2026102121470560500_otag103-B17","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1016\/j.jclinepi.2014.02.019","article-title":"Validation of international algorithms to identify adults with inflammatory bowel disease in health administrative data from Ontario, Canada","volume":"67","author":"Benchimol","year":"2014","journal-title":"J Clin Epidemiol"},{"key":"2026102121470560500_otag103-B18","doi-asserted-by":"publisher","first-page":"e12720","DOI":"10.1111\/cob.12720","article-title":"Healthcare utilization associated with obesity management in Ontario, Canada","volume":"15","author":"Wharton","year":"2025","journal-title":"Clin Obes"},{"key":"2026102121470560500_otag103-B19","author":"Wodchis","year":"2013"},{"key":"2026102121470560500_otag103-B20","doi-asserted-by":"publisher","first-page":"S429","DOI":"10.1016\/j.jval.2022.04.731","article-title":"EE484 evaluation of health care resource utilization and costs among bio-experienced Crohn\u2019s disease patients treated with biologics with two years of follow-up","volume":"25","author":"Cyhaniuk","year":"2022","journal-title":"Value Health"},{"key":"2026102121470560500_otag103-B21","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1093\/ibd\/izz001","article-title":"Real-world pattern of biologic use in patients with inflammatory bowel disease: treatment persistence, switching, and importance of concurrent immunosuppressive therapy","volume":"25","author":"Chen","year":"2019","journal-title":"Inflamm Bowel Dis"},{"key":"2026102121470560500_otag103-B22","doi-asserted-by":"publisher","first-page":"752879","DOI":"10.3389\/fphar.2021.752879","article-title":"Impact of non-persistence on healthcare resource utilization and costs in patients with immune-mediated rheumatic diseases initiating subcutaneous TNF-alpha inhibitors: a before-and-after study","volume":"12","author":"Carballo","year":"2021","journal-title":"Front Pharmacol"},{"key":"2026102121470560500_otag103-B23","doi-asserted-by":"publisher","first-page":"89","DOI":"10.5009\/gnl19023","article-title":"Changes in direct healthcare costs before and after the diagnosis of inflammatory bowel disease: a nationwide population-based study","volume":"14","author":"Lee","year":"2020","journal-title":"Gut Liver"}],"container-title":["Crohn\u2019s &amp; Colitis 360"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/crohnscolitis360\/article-pdf\/8\/4\/otag103\/72109318\/otag103.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/crohnscolitis360\/article-pdf\/8\/4\/otag103\/72109318\/otag103.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T01:47:15Z","timestamp":1792633635000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/crohnscolitis360\/article\/doi\/10.1093\/crocol\/otag103\/8943347"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":23,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,10,5]]}},"URL":"https:\/\/doi.org\/10.1093\/crocol\/otag103","relation":{},"ISSN":["2631-827X"],"issn-type":[{"value":"2631-827X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,10]]},"published":{"date-parts":[[2026,10]]},"article-number":"otag103"}}